Search the Site

The SEC shines a bright light on Allergan’s non-GAAP reporting strategy

Allergan PLC received a  from SEC examiners regarding financial reporting in its 8-k dated 8/8/2016 . The SEC specifically questioned how Allergan approached its calculations of adjusted earnings per share stating “you continue to view your non-GAAP adjusted net income attributable to shareholders, including its presentation on a per share basis, as solely a performance measure.”

In the comment letter, the SEC clearly presents that it disagrees with the approach and left little room for interpretation by stating “In light of our observations, we suggest that you carefully consider Question 102.05 of the updated Non-GAAP Compliance and Disclosure Interpretations and consider ending your practice of providing the per share data.”

Even though the SEC has previously directed registrant’s attention to question 102.05 of the updated Compliance and Disclosure Interpretations, this very direct comment letter could act as an early indicator as to what’s on the horizon regarding how the SEC intends to crackdown on company use of non-GAAP figures.

While Allergan’s compliance machine focuses on its response to its SEC comment letter, it is probably a safe bet that other registrants will be monitoring this exchange closely, along with other SEC favorites related to compliance and disclosure interpretations.

Related Articles

HED: SEC to Stock Exchanges: Your Fees Are Our Business

If a recent ruling by the SEC is any indication, the major U.S. stock exchanges might want to prepare for heavier oversight of their businesses. La...

Digging Deeper on Revenue Recognition

Earlier this week, we released a report on the monumentally important changes to accounting standards for the recognition of revenue from customer con...

Public Companies Stay Tight-Lipped on Midterm Impact

To read the news today is to understand how significantly shifting political winds can affect public companies. But you wouldn’t know it from what t...